80-Week Study Reveals Retatrutide's Powerful Impact on Weight Loss and Blood Sugar Control in Type 2 Diabetes

Triple Action Against Excess Weight

According to НВ — Техно: Researchers have demonstrated the promising effects of retatrutide for individuals living with long-term type 2 diabetes. This innovative experimental drug has shown remarkable success in reducing body weight and regulating blood sugar levels in patients managing the condition for several years. Over an 80-week clinical trial, participants receiving the highest dose experienced significant weight loss alongside improved HbA1c, a key marker of blood sugar control. However, treatment was frequently accompanied by side effects such as nausea and diarrhea.

Study Findings

The trial involved weekly subcutaneous injections of retatrutide or a placebo, combined with lifestyle advice on diet and exercise. Those given 4 mg of the drug lost an average of 11.9% of their initial body weight, while the 9 mg dose group saw a 16.8% reduction. At the maximum 12 mg dose, weight loss reached an impressive 18.8%. In contrast, the placebo group experienced only a 5.1% average weight loss. Blood tests also revealed a sharp decline in HbA1c levels, indicating better glucose management.

Retatrutide functions as a triple agonist by targeting three hormonal receptors: GIP, GLP-1, and glucagon. The study’s participants had an average age of 21 years with a diabetes duration of nearly six years. Notably, 92% of volunteers were already on blood sugar-lowering medications at the start of the trial.

These groundbreaking results were unveiled by Dr. Juan Pablo Frias from the Los Angeles Institute of Metabolic Research at the European Association for the Study of Diabetes annual conference held in Milan on October 13, 2026. Retatrutide represents a potential breakthrough in the treatment of obesity and type 2 diabetes, conditions that continue to affect millions worldwide.

Dr. Juan Pablo Frias, Los Angeles Institute of Metabolic Research

The significance of this study lies in the possibility of incorporating retatrutide into clinical practice for patients facing both type 2 diabetes and obesity. Given the escalating global prevalence of these chronic illnesses, innovative therapies like this one could dramatically improve patient outcomes and quality of life. Nonetheless, the frequent adverse effects observed highlight the necessity for further research to fully assess the long-term safety and effectiveness of retatrutide.

As researchers continue to explore the benefits of retatrutide, it's worth noting that its efficacy surpasses that of existing treatments. A recent study highlights how Eli Lilly’s retatrutide demonstrates significantly greater weight loss compared to Ozempic, achieving up to a 30% reduction in body weight over two years. This comparison underscores the potential of retatrutide as a leading option for those struggling with obesity and type 2 diabetes.